Join Milestone Pharmaceuticals in-person or virtually for a Commercial Launch Plan investor event in New York to provide an overview of its commercial strategy for CARDAMYST for the treatment of paroxysmal supraventricular tachycardia (PSVT). The event will feature presentations by Joseph Oliveto, President and CEO, and Lorenz Muller, Chief Commercial Officer.

Milestone’s New Drug Application (NDA) for CARDAMYST™ (etripamil) nasal spray, its lead investigational product for the management of PSVT, is under review at the U.S. Food and Drug Administration (FDA) with an FDA Prescription Drug User Fee Act (PDUFA) target date of March 27, 2025. Its launch in PSVT is targeted for mid-2025.

A live question and answer session will follow the formal presentation.